Association of CD14 promoter gene polymorphism and Chlamydia pneumoniae infection

Journal of Infectious Diseases

Volumn 188, Issue 1, 2003, Pages 90-97

  Eng, Hock Liew ^a   Chen, Chih Hung ^b   Kuo, Chou Cho ^d   Wu, Jin Shang ^b   Wang, Chiou Huey ^b,c   Lin, Tsun Mei ^b,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOSINE; TYROSINE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HEALTH STATUS; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE REGRESSION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SEROLOGY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, CD14; ARTERIOSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SOLUBILITY;

EID: 0038235643     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/375744     Document Type: Article

References (56)

1. Pugin J, Heumann ID, Tomasz A, et al. CD14 is a pattern recognition receptor. Immunity 1994; 1:509-16.
2. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
3. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001; 276:21129-35.
4. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000; 343:338-44.
5. Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176:1665-71.
6. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976-83.
7. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30:969-73.
8. Zhang DE, Hetherington CJ, Tan S, et al. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem 1994; 269:11425-34.
9. Hubacek JA, Pit'ha J, Skodova Z, Stanek V, Poledne R. C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99:3218-20.
10. Karhukorpi J, Yan Y, Niemela S, et al. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol 2002; 128:326-32.
11. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-26.
12. Valtonen VV. Infection as a risk factor for infarction and atherosclerosis. Ann Med 1991; 23:539-43.
13. Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction and stroke. Clin Infect Dis 1998; 26:719-34.
14. Saikku P, Leinonen M, Marttila K. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2:983-6.
15. Kuo CC, Shor A, Campbell LA. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167:841-9.
16. Kuo CC, Jackson L, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8:451-61.
17. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998; 177:1322-5.
18. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350:430-6.
19. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995; 92:6911-4.
20. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82:158-61.
21. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176:292-5.
22. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633-6.
23. Moazed TC, Kuo CC, Grayston JT, Compbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175:883-90.
24. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS Study. Eur Heart J 1999; 20:121-7.
25. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebo-controlled trial. Lancet 2001; 357:2085-9.
26. Unkelbach K, Gardemann A, Kostrewa M, Philipp M, Tillmanns H, Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19:932-8.
27. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85:584-95.
28. Boekholdt SM, Bijsterveld NK, Moons AHM, Levi M, Buller HR, Peters RJG. Genetic variation in coagulation and fibrinolylic proteins and their relation with acute myocardial infarction. Circulation 2001; 104:3063-8.
29. Andreotti FA, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischemic heart disease: review of population association studies. Heart 2002; 87:107-12.
30. Wang SP, Grayston JT. Microimmunofluorescence serological studies with the TWAR organism. In: Oriel JD, Ridgeway G, Schachter J, Taylor Robinson D, Ward M, eds. Chlamydial infections. Cambridge, MA: Cambridge University Press, 1986:329-32.
31. Grayston JT, Wang SP, Kuo CC, Campbell LA. Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory disease. Eur J Clin Microbiol Infect Dis 1989; 8:191-202.
32. Zee RY, Lindpaintner K, Struk B, Hennekens CH, Ridker PM. A prospective evaluation of the CD14 (-260) T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001; 154:699-702.
33. Leinonen M, Saikku P. Interaction of CP infection with other risk factors of atherosclerosis. Am Heart J 1999; 138:S504-6.
34. Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydial pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995; 114:165-74.
35. Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with CP infection. J Am Coll Cardiol 2001; 38:712-7.
36. Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000; 86:682-4.
37. Zee RY, Bates D, Ridker PM. A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of stroke. Stroke 2002; 33:892-5.
38. Koenig W, Khuseyinova N, Hoffmann MM, et al. CD14 C(-260)→T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infection and risk of stable coronary artery disease. J Am Coll Cardiol 2002; 40:34-42.
39. Wang JH, Liu YC, Cheng DL, Yeng MY, Chen YS, Chen BC. Seroprevalence of Chlamydia pneumoniae in Taiwan. Scand J Infect Dis 1993; 25:565-8.
40. Wong PMC, Chung SW, Sultzer BM. Gene receptors, signals and responses to lipopolysaccharide endotoxin. Scand J Immunol 2000; 51:123-7.
41. Schumann RR, Pfeil D, Lamping N, et al. Lipopolysaccharide induces the rapid tyrosine phosphorylation of the mitogen-activated protein erk-1 and p38 in cultured human vascular endothelial cells required the presence of soluble CD14. Blood 1996; 87:2805-14.
42. Sanlioglu S, Williams CM, Samavati L, et al. Lipopolysaccharide induces Rac-1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-α secretion through IKK regulation of NF-kB. J Biol Chem 2001; 276:30188-98.
43. LeVan TD, Bloom JW, Bailey TJ, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001; 167:5838-44.
44. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1 and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health study. Circulation 2000; 102:2335-40.
45. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. Stroke 1999; 30:299-305.
46. Cook PJ, Honeybourne D, Lip GY, Beever DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke 1998; 29:404-10.
47. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99:1161-4.
48. Haider AW, Wilson PW, Larson MG, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol 2002; 40:1408-13
49. Heesen M, Blomeke B, Schluter B, Heussen N, Rossaint R, Kunz D. Lack of association between the -260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med 2001; 27:1770-5.
50. Ito D, Murata M, Tanahashi N, et al. Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke 2000; 31:2661-4.
51. Vercelli D, Baldini M, Martinez F. The monocyte/IgE connection: may polymorphisms in the CD14 gene teach us about IgE regulation? Int Arch Allergy Immunol 2001; 124:20-4.
52. Heinemann M, Susa M, Simnacher U, Marre R, Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in human monocytic cell line. Infect Immun 1996; 64:4872-5.
53. Hubacek JA, Stuber F, Frohlich D, et al. The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000; 1:405-7.
54. Heesen M, Bloemeke B, Schade U, Obertacke U, Majetschak M. The -260 C→T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med 2002; 28:1161-3.
55. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutation but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186:1522-5.
56. Netea MG, Kullberg BJ, Galama JMD, Stalenhoef AFH, Dinarello CA, Van der Meer JWM. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol 2002; 32:1188-95.